Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

N/A

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01551498Phase 2Completed

Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)

Role: lead

NCT01740934Not ApplicableCompleted

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Role: lead

NCT02432313Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations

Role: lead

NCT01262170Phase 1Completed

A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers

Role: lead

NCT01428310Phase 1Completed

Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke

Role: lead

NCT01669876Phase 2Terminated

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

Role: lead

All 6 trials loaded